In this issue of *EBioMedicine*, Liping Zhao and colleagues show that children with obesity have similar gut microbiota dysbiosis regardless of their genetic makeup, whether it is simple obesity (no underlying pathology) or genetic obesity (Prader--Willi syndrome). Furthermore, their microbiome profile can be changed by a 1-month dietary intervention. Interestingly, the authors also show that transfer of pre-intervention fecal microbiota from these children to germ-free mice recapitulates key obesity-related traits, an effect that is not seen if post-intervention fecal microbiota from the same children is transplanted, suggesting a possible causative contribution of gut microbiota to obesity development.

Microbes inhabit various niches of the human body, from the skin to oronasal and urogenital cavities, but the vast majority is found in the human gastrointestinal tract. Microbes outnumber human cells at a ratio of 10 to 1, and microbial genes outnumber human genes by over 100 to 1. Commensal microbes have an important role in digesting food and providing nutrients, in educating our immune system and in protecting us from infection. More than 30% of small molecules found in human blood are derived from microbes. Using high-throughput molecular technologies, large collaborative projects such as the European Commission-funded MetaHIT and the US NIH-funded Human Microbiome Project are aiding the discovery of increasingly important insights into the role of the microbiome in human health.

The field of *microbiomics* holds a lot of hope, but at the same time, microbiome research also has the potential to create much hype. We must be cautious in interpreting overly positive news headlines, because most studies to date are based on small numbers, their findings are often preliminary, descriptive, and sometimes even contradictory. The human microbiome has been linked to a plethora of diseases, ranging from gastrointestinal conditions (inflammatory bowel disease, colorectal cancer) and metabolic syndromes (diabetes, obesity), to seemingly unrelated diseases such as rheumatoid arthritis, cardiovascular diseases (atherosclerosis), neurological disorders (multiple sclerosis, Alzheimer\'s disease), and mental health (anxiety, depression, autism). But how many of these links are true causal relationships? In microbiome research, many confounding factors need to be controlled for --- for example, diet is a major confounder that can affect both gut microbiota and obesity. For therapeutic applications, evidence for causality is crucial along with the underlying mechanisms of action. Thus, even when a correlation between the microbiome and health is sufficiently robust and reproducible, the application of such findings beyond diagnostic or prognostic use is not immediately apparent. Researchers urgently need to transition away from purely descriptive work toward more mechanistic studies.

Another significant hurdle is how well microbiome research findings are translated in real-life situations. The majority of translational work to date has been focused on preclinical experiments using germ-free animals, which do not represent the animal\'s natural state. Nonetheless, germ-free animals have been a vital tool in microbiome research and have helped answer simple questions, such as whether behavioral traits can be transferred via fecal microbiota transplant (FMT). Germ-free mice receiving FMT from patients with irritable bowel syndrome (IBS) developed leaky intestines and produced proinflammatory metabolites, many of which are known neurotransmitters. These animals also displayed anxious behavior, and indeed anxiety and depression are often observed in IBS patients, but the pathogenesis remains elusive. Ongoing research into the brain--gut axis has also shed light on how glia cells and neurons of the brain and gut may communicate. Observations such as these can be pieced together to build a more complete picture of the complex interactions and associations.

While we should not let our interpretations and related clinical decisions be driven by the hyperboles surrounding how gut microbes might affect human health, there are some useful advances in our knowledge that allow for clinical application. *Clostridium difficile* infection (CDI), which most commonly occurs in individuals whose gut microbiota have been displaced as a result of antibiotic treatment, can manifest as severe diarrhea especially in those over 65 years of age. Stopping antibiotics (to allow gut microbiota to recover) or treating with CDI-specific antibiotics (e.g., vancomycin) is not always successful --- and among those with treatment failure, one in three will die. FMT is a newly available treatment for relapsed CDI in the UK and USA, in which fecal microbiota from a healthy donor can alleviate diarrheal symptoms within 1--2 days for more than 90% of patients.

The paper by Zhao and colleagues suggests a housekeeping role for *Bifidobacterium* species in maintaining gut homeostasis and a healthy gut ecosystem. Whether or not *Bifidobacterium* plays an active role in the success of FMT in CDI treatment remains to be determined. But in keeping with the US NIH Precision Medicine Initiative, future research should focus on delineating the microbial subspecies that have a positive effect on CDI treatment, which would inform a better-characterized, mechanistically-defined, microbiome-targeted intervention. Although CDI is currently the only indication for which FMT is approved outside of a clinical trial, the hundreds of other ongoing FMT trials will hopefully soon yield useful and effective interventions for many other health conditions.
